Enovis (ENOV) Stock: Buy, Sell, or Hold?
ENOV - Enovis Corporation
$18.05
-0.22 (-1.20%)
▼
5d:
-1.2%
30d:
-12.08%
90d:
-19.78%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ENOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ENOV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ENOV shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.57
Based on 2.7% avg growth
INTRINSIC VALUE TODAY
$16.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ENOV is currently trading at $18.05, which is considered slightly low relative to its 30-day fair value range of $17.46 to $23.32. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.9) compared to its historical average (6.3). Remarkably, the market is currently pricing in an annual earnings decline of 8.3% over the next few years. This pessimistic expectation contrasts with the company's recent 153.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $17.47, while resistance sits at $18.79.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $38.33 (+112.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ENOV is in a downtrend. Immediate support is located at $17.47, while resistance sits at $18.79.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $38.33 (+112.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$17.46 -
$23.32
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.4% below Wall St target ($38.33)
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$17.46 -
$23.32
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$17.47
Resistance Level
$18.79
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.89
Wall Street Target
$38.33
(+112.4%)
Revenue Growth (YoY)
3.2%
Earnings Growth (YoY)
153.1%
Profit Margin
-48.0%
Valuation Discount vs History
-8.3% cheaper
PE vs Historical
4.9 vs 6.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.3%
(market-implied from PE analysis)
1-Year Target
$16.55
(-8%)
2-Year Target
$15.18
(-16%)
3-Year Target
$13.92
(-23%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$17.94
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 1.4%)
$78.64
(+336%)
Base:
(SPY PE: 4.9, Growth: 1.4%)
$18.85
(+4%)
Bear:
(PE: 4.2, Growth: 1.4%)
$16.02
(-11%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.9 to 6.3
Stabilization Target:
$23.26
(+28.9%)
PE Expansion Potential:
+28.9%
Share & Embed Analysis
Last updated: October 01, 2026 5:01 PM ET
Data refreshes hourly during market hours. Next update: 6:01 PM
Data refreshes hourly during market hours. Next update: 6:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
